ClinicalTrials.Veeva

Menu
The trial is taking place at:
D

DermResearch, Inc. | Austin, TX

Veeva-enabled site

Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA

P

Pelage Pharmaceuticals, Inc.

Status and phase

Enrolling
Phase 2

Conditions

Androgenetic Alopecia

Treatments

Drug: PP405 Topical Vehicle Gel
Drug: PP405 0.05% Topical Gel

Study type

Interventional

Funder types

Industry

Identifiers

NCT06393452
PP405-2001

Details and patient eligibility

About

The study is designed to validate safety results from the Phase 1 PP405-001 trial while also characterizing longer term safety and PK following 28 days of administration.

Full description

Safety, Pharmacokinetics, and Efficacy Study of PP405 in subjects with Androgenetic Alopecia.

Enrollment

60 estimated patients

Sex

All

Ages

18 to 55 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Male or female subjects aged 18 to 55 years.
  2. Able and willing to provide written informed consent.
  3. Males must have an AGA modified Norwood-Hamilton Classification score of Type III vertex, Type IV or Type V. Females must have a Savin classification score of I-2, I-3 or I-4.
  4. Agree to comply with protocol procedures

Exclusion criteria

  1. Concomitant diagnosis of non-AGA forms of alopecia.
  2. Use of other hair loss treatments within periods specified in protocol.
  3. Use of excluded medications as specified in protocol.
  4. Diagnosis of other medical conditions as specified in protocol.
  5. Any disease or medical condition that, in the opinion of the Investigator, would prevent the subject from participating in the study or might confound study results.

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

60 participants in 2 patient groups, including a placebo group

PP405 0.05% Topical Gel
Active Comparator group
Description:
0.05% Topical Gel applied once daily
Treatment:
Drug: PP405 0.05% Topical Gel
PP405 Topical Vehicle Gel
Placebo Comparator group
Description:
Placebo Topical Gel applied once daily
Treatment:
Drug: PP405 Topical Vehicle Gel

Trial contacts and locations

8

Loading...

Central trial contact

Lisa Sherman

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems